GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » 3-Year EPS without NRI Growth Rate

Fusion Antibodies (LSE:FAB) 3-Year EPS without NRI Growth Rate : -46.20% (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies 3-Year EPS without NRI Growth Rate?

Fusion Antibodies's EPS without NRI for the six months ended in Sep. 2023 was £-0.03.

During the past 3 years, the average EPS without NRI Growth Rate was -46.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Fusion Antibodies was 34.50% per year. The lowest was -46.20% per year. And the median was -15.75% per year.


Competitive Comparison of Fusion Antibodies's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Fusion Antibodies's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Antibodies's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's 3-Year EPS without NRI Growth Rate falls into.



Fusion Antibodies 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Fusion Antibodies  (LSE:FAB) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Fusion Antibodies 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies (LSE:FAB) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022